5-O-甲基胸腺嘧啶脱氧核苷 | 14504-60-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 中文名称: 5-O-甲基胸腺嘧啶脱氧核苷
• 英文名称: 5'-O-methylthymidine
• 英文别名: 5'-O-Methyl-thymidin；1-[(2R,4S,5R)-4-hydroxy-5-(methoxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
• CAS: 14504-60-0
• 化学式: C₁₁H₁₆N₂O₅
• 分子量: 256.258
• InChiKey: KTCKNHCDUKONFQ-DJLDLDEBSA-N

物化性质

• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  88.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5'-O-(1,3-benzodithiol-2-yl)thymidine 在 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 甲苯 为溶剂， 反应 6.0h， 生成 5-O-甲基胸腺嘧啶脱氧核苷
  参考文献：
  名称：

  [[2-(Methylthio)phenyl]thio]methyl (MTPM): a new protecting group of hydroxyl groups capable of conversion to a methyl group

  摘要：

  DOI：

  10.1021/jo00286a041

文献信息

• [EN] COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE SYNTHÈSE DE MOLÉCULES PHOSPHORYLÉES
  申请人：UNIV CALIFORNIA

  公开号：WO2019195494A1

  公开（公告）日：2019-10-10

  The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.

  这项发明提供了合成磷酸化有机化合物的组合物和方法，包括核苷三磷酸。
• [EN] HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE HAT ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：ABBVIE INC

  公开号：WO2016044777A1

  公开（公告）日：2016-03-24

  Compounds having a structure of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R3c, R4a, R4b, R5, R6, Z and X are as defined herein are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

  提供具有公式I结构或其立体异构体、互变异构体或药学上可接受的盐的化合物，其中R1、R2a、R2b、R3a、R3b、R3c、R4a、R4b、R5、R6、Z和X如本文所定义。还提供包含这些化合物的药物组合物以及通过给予这些化合物治疗各种HAT相关病症或疾病，包括癌症的方法。
• [EN] 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE SUBSTITUES EN POSITION 4
  申请人：BIOAXONE THERAPEUTIQUE INC

  公开号：WO2005080394A1

  公开（公告）日：2005-09-01

  Substituted piperidine compounds represented by the structure I are provided, wherein each of Rla, R1b, R1c, R1d, Rle, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x, and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

  提供了由结构I表示的取代哌啶化合物，其中Rla、R1b、R1c、R1d、Rle、R1f、R1g、R1h、R2、R2A、R3、R4、A、X、a、x和n中的每一个如规范中定义。结构I的取代哌啶化合物可能渗透或穿过神经细胞膜进入神经细胞内部，可能抑制哺乳动物神经细胞中的细胞内Rho激酶酶，并可能在这些哺乳动物的中枢和外周神经系统中修复受损神经时发挥作用。这些化合物可能诱导哺乳动物神经细胞中神经突起的再生或生长，从而诱导受损或患病神经组织的再生。这些化合物还可作为Rho激酶酶拮抗剂在治疗涉及Rho激酶的疾病状态中发挥额外作用。含有这些取代哌啶化合物的药物组合物可能有助于促进神经突起的生长，并在需要Rho激酶抑制的疾病治疗中发挥作用。
• Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
  申请人：Houlmont Jean-Philippe

  公开号：US20070134187A1

  公开（公告）日：2007-06-14

  The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C 2 -C 40 , said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The invention also relates to a cosmetic treatment method involving the topical application of a composition comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C 2 -C 40 .

  该发明涉及一种药物，包括至少一种含有羟基功能的还原烷基糖单体，该羟基功能在C2-C40处被烷氧基取代，所述药物通常用于调节炎症机制。还原糖通常选自包含鼠李糖、岩藻糖和葡萄糖的组。该发明还涉及一种化妆品处理方法，涉及局部应用包含至少一种含有羟基功能的还原烷基糖单体，该羟基功能在C2-C40处被烷氧基取代的组合物。
• [EN] 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS<br/>[FR] NUCLÉOSIDES SUBSTITUÉS EN POSITION 2',4' EN TANT QU'AGENTS ANTIVIRAUX
  申请人：PHARMASSET INC

  公开号：WO2009067409A1

  公开（公告）日：2009-05-28

  Embodiments of the invention are to compounds of formulae (A), (A'), methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention aur 2 ', 4 ' -substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.

  本发明的实施例涉及公式（A）、（A'）的化合物，方法和组合物，用于治疗病毒感染。更具体地，本发明的实施例为用于治疗病毒感染，如HIV、HCV和HBV感染的2'，4'-取代核苷化合物。